BHC.TO

Bausch Health Companies Inc. [BHC.TO] Stock Forecast

Q: What is Bausch Health Companies Inc. stock symbol ?

Bausch Health Companies Inc. is a CA stock, located in Laval of Qc and trading under the symbol BHC.TO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

BHC.TO Stock Summary

Earnings have grown 7.79% per last year.

Earnings are expected to fall -100% next year

Profit margins (-0.11%) are lower than the previous year (-0.07%)

BHC.TO has less than 1 year of cash runway

Top 10 Correlated ETFs

BHC.TO

Top 10 Correlated Stocks

BHC.TO

In the News

BHC.TO Financial details

Company Rating

Sell

Market Cap

4.41B

Income

-600M

Revenue

8.76B

Book val./share

-2.88

Cash/share

2.67

Dividend

Dividend %

Employees

20.27K

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

-3.15

Forward P/E

PEG

-0.18

P/S

0.36

P/B

-3.48

P/C

4.43

P/FCF

-4.98

Quick Ratio

0.59

Current Ratio

1.12

Debt / Equity

-21.91

LT Debt / Equity

-267.54

EPS (TTM)

-1.65

EPS next Y

EPS next Q

EPS this Y

174.58%

EPS next Y

EPS next 5Y

EPS last 5Y

-20.4%

Revenue last 5Y

0.36%

Revenue Q/Q

7.6%

EPS Q/Q

-89.32%

SMA20

-7.69%

SMA50

9.09%

SMA100

33.33%

Inst Own

Inst Trans

ROA

-3%

ROE

134%

ROC

0.03%

Gross Margin

71%

Oper. Margin

12%

Profit Margin

-11%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

7.56-15.43

52W High

-21.13%

52W Low

+69%

RSI

Rel Volume

0.42

Avg Volume

358.08K

Volume

150.78K

Perf Week

-3.66%

Perf Month

-5.06%

Perf Quarter

28.03%

Perf Half Y

11.6%

Beta

0.861

Volatility

0.1%, 0.77%

Prev Close

-0.08%

Price

11.83

Change

-0.59%

BHC.TO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	24.44	22.65	23.5	22.44	24
Net income per share	-5.07	-1.58	-2.61	-0.59	-1.62
Operating cash flow per share	4.26	3.13	3.97	-2.01	2.83
Free cash flow per share	3.47	2.26	3.18	-2.75	2.08
Cash per share	9.21	1.71	1.62	1.56	2.6
Book value per share	3.02	1.51	-0.3	-1.91	-2.8
Tangible book value per share	-63.05	-58.92	-54.16	-47.2	-48.56
Share holders equity per share	3.02	1.51	-0.3	-1.91	-2.8
Interest debt per share	78.15	71.83	67.09	61.41	64.99
Market cap	10.53B	7.35B	9.84B	2.27B	2.92B
Enterprise value	33.18B	30.67B	31.91B	22.47B	24.37B
P/E ratio	-5.9	-13.15	-10.5	-10.71	-4.94
Price to sales ratio	1.22	0.92	1.17	0.28	0.33
POCF ratio	7.01	6.62	6.9	-3.12	2.83
PFCF ratio	8.61	9.16	8.61	-2.28	3.85
P/B Ratio	9.9	13.74	-92.83	-3.28	-2.86
PTB ratio	9.9	13.74	-92.83	-3.28	-2.86
EV to sales	3.86	3.82	3.78	2.77	2.78
Enterprise value over EBITDA	18.19	12.18	12.34	8.69	8.43
EV to operating cash flow	22.1	27.61	22.38	-30.87	23.61
EV to free cash flow	27.13	38.24	27.92	-22.56	32.06
Earnings yield	-0.17	-0.08	-0.1	-0.09	-0.2
Free cash flow yield	0.12	0.11	0.12	-0.44	0.26
Debt to equity	24.36	44.72	-213.72	-30.01	-21.91
Debt to assets	0.76	0.77	0.78	0.81	0.82
Net debt to EBITDA	12.42	9.26	8.54	7.82	7.42
Current ratio	1.12	1.09	1.08	1.08	1.3
Interest coverage	-0.05	0.44	0.85	0.94	0.73
Income quality	-0.84	-1.99	-1.52	3.43	-1.69
Dividend Yield	0	0	0	0.01	0
Payout ratio	0	0	0	-0.15	0
Sales general and administrative to revenue	0.23	0.24	0.25	0.26	0
Research and developement to revenue	0.05	0.06	0.06	0.07	0.07
Intangibles to total assets	0.69	0.69	0.66	0.68	0.64
Capex to operating cash flow	-0.19	-0.28	-0.2	0.37	-0.26
Capex to revenue	-0.03	-0.04	-0.03	-0.03	-0.03
Capex to depreciation	-0.13	-0.17	-0.18	-0.19	-0.22
Stock based compensation to revenue	0.01	0.01	0.02	0.02	0.02
Graham number	18.55	7.32	4.17	5.02	10.11
ROIC	0	0.02	0.05	0.11	0.07
Return on tangible assets	-0.17	-0.06	-0.1	-0.03	-0.06
Graham Net	-78.28	-79.73	-74.75	-63.47	-66.36
Working capital	721M	429M	409M	306M	1.29B
Tangible asset value	-22.19B	-20.88B	-19.44B	-17.09B	-17.72B
Net current asset value	-25.76B	-25.25B	-23.63B	-21.18B	-21.84B
Invested capital	24.36	44.72	-213.72	-30.01	-21.91
Average receivables	1.85B	1.71B	1.68B	1.78B	1.89B
Average payables	457M	420M	372M	464M	620M
Average inventory	1.02B	1.1B	1.04B	1.04B	1.32B
Days sales outstanding	78.04	71.71	76.82	80.42	83.28
Days payables outstanding	78.13	54.69	62.05	80.44	102.55
Days of inventory on hand	171.94	177.55	151.4	168.3	220.23
Receivables turnover	4.68	5.09	4.75	4.54	4.38
Payables turnover	4.67	6.67	5.88	4.54	3.56
Inventory turnover	2.12	2.06	2.41	2.17	1.66
ROE	-1.68	-1.04	8.84	0.31	0.58
Capex per share	-0.79	-0.87	-0.79	-0.74	-0.75

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	6.06	5.35	5.94	6.12	6.79
Net income per share	-1.13	-0.58	0.07	-1.03	-0.11
Operating cash flow per share	1.31	0.42	0.74	0.77	1.1
Free cash flow per share	1.05	0.28	0.63	0.65	0.69
Cash per share	1.56	1.43	2.1	2.08	2.67
Book value per share	-1.91	-2.2	-2.41	-3.23	-2.88
Tangible book value per share	-47.21	-46.75	-60.51	-49.67	-49.98
Share holders equity per share	-1.91	-2.2	-2.41	-3.23	-2.88
Interest debt per share	58.23	57.69	75.53	62.31	64.17
Market cap	2.27B	2.94B	3.87B	2.99B	2.84B
Enterprise value	22.47B	23.08B	30.34B	24.66B	24.28B
P/E ratio	-1.38	-3.52	37.18	-1.98	-18.21
Price to sales ratio	1.04	1.51	1.78	1.34	1.18
POCF ratio	4.78	19.1	14.39	10.61	7.29
PFCF ratio	5.99	28.56	16.88	12.68	11.55
P/B Ratio	-3.28	-3.68	-4.4	-2.54	-2.78
PTB ratio	-3.28	-3.68	-4.4	-2.54	-2.78
EV to sales	10.25	11.87	14	11.02	10.08
Enterprise value over EBITDA	31.65	48.38	40.94	35.59	28.94
EV to operating cash flow	47.31	149.85	112.86	87.45	62.26
EV to free cash flow	59.29	224.05	132.42	104.5	98.71
Earnings yield	-0.18	-0.07	0.01	-0.13	-0.01
Free cash flow yield	0.17	0.04	0.06	0.08	0.09
Debt to equity	-30.01	-25.82	-31	-19.01	-21.91
Debt to assets	0.81	0.81	0.81	0.83	0.82
Net debt to EBITDA	28.45	42.21	35.72	31.27	25.56
Current ratio	1.08	1.08	1.12	1.2	1.3
Interest coverage	1.29	0.57	1.29	0.04	1
Income quality	-1.16	-0.74	6.48	-0.74	-8.3
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.07	0	0	0	0
Research and developement to revenue	0.06	0.07	0.07	0.07	0.06
Intangibles to total assets	0.68	0.67	0.66	0.66	0.64
Capex to operating cash flow	-0.2	-0.33	-0.15	-0.16	-0.37
Capex to revenue	-0.04	-0.03	-0.02	-0.02	-0.06
Capex to depreciation	-0.27	-0.16	-0.1	-0.15	-0.44
Stock based compensation to revenue	0.02	0.02	0.02	0.01	0.01
Graham number	6.98	5.34	1.97	8.67	2.67
ROIC	0.02	0.01	0.01	0	0.11
Return on tangible assets	-0.05	-0.03	0	-0.04	0
Graham Net	-63.48	-63.05	-82.56	-66.89	-68.3
Working capital	306M	314M	654.65M	824M	1.29B
Tangible asset value	-17.09B	-16.99B	-22.07B	-18.15B	-17.72B
Net current asset value	-21.18B	-21.06B	-27.53B	-22.25B	-21.84B
Invested capital	-30.01	-25.82	-31	-19.01	-21.91
Average receivables	1.76B	1.74B	2B	2.13B	1.97B
Average payables	503.5M	541M	621.74M	625.74M	644M
Average inventory	1.07B	1.16B	1.43B	1.46B	1.41B
Days sales outstanding	73.46	78.15	95.93	78.34	74.68
Days payables outstanding	71.92	86.75	94.64	82.2	91.79
Days of inventory on hand	150.46	188.97	227.88	183.76	197.11
Receivables turnover	1.23	1.15	0.94	1.15	1.21
Payables turnover	1.25	1.04	0.95	1.09	0.98
Inventory turnover	0.6	0.48	0.39	0.49	0.46
ROE	0.59	0.26	-0.03	0.32	0.04
Capex per share	-0.27	-0.14	-0.11	-0.13	-0.41

BHC.TO Frequently Asked Questions

What is Bausch Health Companies Inc. stock symbol ?

Bausch Health Companies Inc. is a CA stock , located in Laval of Qc and trading under the symbol BHC.TO

What is Bausch Health Companies Inc. stock quote today ?

Bausch Health Companies Inc. stock price is $11.83 today.

Is Bausch Health Companies Inc. stock public?

Yes, Bausch Health Companies Inc. is a publicly traded company.

Something similar

Top by Market Cap

TSLA

ABEC.DE

AVGO

Company Profile

Volume Average 358.08K
Market Capitalization 4.41B
Employee 20.27K
CEO Mr. Thomas J. Appio
Headquarters Laval,QC,CA
IPO Date 1996-04-03
Website https://www.bauschhealth.com

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.